Neumora Therapeutics (NMRA) grants CEO 500K stock options

Rhea-AI Filing Summary

Neumora Therapeutics, Inc. (NMRA) reported that its President & CEO, Joshua Pinto, received a grant of stock options for 500,000 shares of common stock. The options have an exercise price of $1.52 per share and expire on August 20, 2036. According to the vesting terms, 25% of the shares subject to the option vest on the first anniversary of the August 20, 2026 vesting commencement date, and the remaining shares vest in equal monthly installments over the following three years.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pinto Joshua

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	500,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 500,000 shares (Direct)

Footnotes (1)

1. F1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

Key Figures

Stock options granted: 500,000 shares Exercise price: $1.52 per share Expiration date: August 20, 2036 +3 more

6 metrics

Stock options granted 500,000 shares Stock Option (Right to Buy) grant to President & CEO Joshua Pinto

Exercise price $1.52 per share Conversion or exercise price of the stock option grant

Expiration date August 20, 2036 Expiration date of the stock option grant

Shares underlying option 500,000 shares Underlying common stock for the stock option grant

Initial vesting portion 25% of shares Vests on the first anniversary of the August 20, 2026 Vesting Commencement Date

Ongoing vesting rate 1/48th of total shares monthly Remaining vesting after the first anniversary until fully vested on the fourth anniversary

Key Terms

Stock Option (Right to Buy), Vesting Commencement Date, fully vested and exercisable

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

Vesting Commencement Date financial

"measured from August 20, 2026 (the "Vesting Commencement Date")"

The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.

fully vested and exercisable financial

"100% of the shares subject to the option will be fully vested and exercisable"

FAQ

What did NMRA CEO Joshua Pinto report on this Form 4?

He reported a grant of stock options for 500,000 shares of Neumora Therapeutics, Inc. common stock, with an exercise price of $1.52 per share and an expiration date of August 20, 2036, held as direct ownership.

What is the exercise price of the new NMRA stock options?

The stock options granted to Joshua Pinto have an exercise price of $1.52 per share for Neumora Therapeutics, Inc. common stock, as disclosed in the Form 4 filing.

How many NMRA shares are covered by the new stock option grant?

The stock option grant covers 500,000 shares of Neumora Therapeutics, Inc. common stock. Following this grant, the reported option position is 500,000 derivative securities related to the company’s common stock.

What is the vesting schedule for the NMRA options granted to the CEO?

The filing states that 25% of the shares vest on the first anniversary of the August 20, 2026 Vesting Commencement Date, and 1/48th of the total shares vest monthly thereafter, so that 100% are fully vested and exercisable on the fourth anniversary of that date.

When do the newly granted NMRA stock options expire?

The stock options granted to Joshua Pinto expire on August 20, 2036, as stated in the Form 4. After this date, any unexercised portion of the 500,000-share option would no longer be exercisable.

Are the NMRA options reported on this Form 4 already exercisable?

The options are not fully exercisable immediately. The filing states that they begin vesting based on a Vesting Commencement Date of August 20, 2026, with vesting over four years until 100% are fully vested and exercisable on the fourth anniversary of that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/21/2026 - 07:06 PM Accepted by SEC EDGAR 08/21/2026 - 07:06 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pinto Joshua

(Last) (First) (Middle)

C/O NEUMORA THERAPEUTICS, INC.

260 ARSENAL PLACE, SUITE 1

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Neumora Therapeutics, Inc. [ NMRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.52	08/20/2026		A		500,000		(1)	08/20/2036	Common Stock	500,000	$0	500,000	D

Explanation of Responses:

1. 25% of the shares subject to the option vest on the first anniversary measured from August 20, 2026 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date.

	/s/ Michael Milligan, as Attorney-in-Fact for Joshua Pinto	08/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)